The reference implanted VNS device — the clinical gold standard, not a consumer purchase.
Reference medical device for understanding what non-invasive consumer VNS can and cannot replicate.
LivaNova VNS Therapy is the implanted vagus nerve stimulator that defined the modern VNS category. A pulse generator is surgically placed under the collarbone and wired to the left cervical vagus nerve; programming is done by a clinician. FDA-approved for drug-resistant epilepsy since 1997 and treatment-resistant depression since 2005. Included here as the medical reference point for understanding what non-invasive devices can and cannot replicate.
How we tested: Evidence-based assessment — scored from LivaNova clinical documentation, FDA-approved labelling and the published VNS Therapy registry literature. Included as the medical reference point for the category, not as a consumer recommendation.
Twenty-plus years of FDA-approved use, hundreds of peer-reviewed studies, registry data from 100,000+ implanted patients. The reference VNS evidence base.
Stimulation mechanism
9.5
Direct electrical stimulation of the cervical vagus nerve via surgically-implanted lead — the most direct stimulation possible. Programmable duty cycle, amplitude and frequency.
Protocol flexibility
8.5
Clinician-programmed continuous duty cycle plus closed-loop AutoStim (responsive to heart-rate changes in seizure prediction). Not user-adjustable by design.
Comfort and wearability
5.0
Surgical implant; post-operative scar and possible voice/throat side effects during stimulation. Lifetime device.
−Restricted to clinically-indicated patients with prescribing specialist
−Voice change and throat discomfort during stimulation are common
−Procedure costs are insurance-mediated; not directly purchasable
Price: $27500 procedure + device; typically insurance-covered for indicated conditions (as of 2026-05-21)
Where it leads
LivaNova VNS Therapy is included in this list as the reference point — the implanted device that every non-invasive vagus stimulator is trying to approximate at one degree of indirection. A pulse generator the size of a small pocket watch is surgically placed under the left collarbone and wired to the cervical vagus nerve; the device fires on a clinician-programmed duty cycle and (in the SenTiva variant) closes the loop with on-device ECG-based seizure prediction. The evidence base is overwhelming: FDA-approved since 1997 for drug-resistant epilepsy and since 2005 for treatment-resistant depression, with registry data on more than 100,000 implanted patients and hundreds of peer-reviewed studies.
Where it falls short
It is a surgical implant. The patient pathway is a neurosurgeon, a hospital procedure, post-operative recovery, lifetime carriage of the device, and the well-documented intermittent side effects — voice change and throat discomfort during stimulation cycles. It is restricted to clinically-indicated patients with prescribing specialist sign-off, and costs are insurance-mediated rather than directly purchasable.
Who it is for
Not a consumer recommendation. LivaNova VNS Therapy is the gold-standard medical device for drug-resistant epilepsy and treatment-resistant depression — the right tool for the people meeting those criteria, prescribed by a specialist. For everyone else, non-invasive cervical (gammaCore, Truvaga) or auricular (Nurosym, Vagustim) devices approximate the mechanism without surgery, at known cost to the strength of the effect.
Background reading
The biology behind what these devices target — and the protocols that compound with the hardware.